Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 4, 2021Andrew Drechsler to Retire as Chief Financial Officer in December
-
Oct 26, 2021PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers
-
Oct 25, 2021Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
-
Oct 22, 2021Pivotal trial met primary and all key secondary endpoints
-
Oct 20, 2021Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
-
Oct 7, 2021First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
-
Sep 28, 2021Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza
-
Sep 19, 2021*Phase 3 trial met its primary and key secondary endpoints
-
Sep 13, 2021Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy
-
Aug 30, 2021Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
-
Aug 6, 2021Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile
-
Aug 5, 2021Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death
-
Jul 29, 2021Fifth disease that Dupixent has demonstrated positive pivotal results
-
Jul 12, 2021Designation is the first step in a new MHRA initiative to accelerate the development and access to innovative medicines in the UK post-Brexit
-
Jul 6, 2021Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstanding
-
Jul 2, 2021New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented
-
Jun 28, 2021* Study also shows more people on Soliqua 100/33 had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin
-
Jun 28, 2021- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2